Keratoacanthoma
-
Risk of secondary tumors from melanoma drug studied
A new study offers clues on why melanoma patients who are treated with oral drugs inhibiting the BRAF gene are at increased risk for developing secondary skin cancers. Read MoreMar 23, 2012